News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
571,880 Results
Type
Article (18587)
Company Profile (153)
Press Release (553048)
Multimedia
Podcasts (11)
Webinars (12)
Section
Business (188921)
Career Advice (549)
Deals (28753)
Drug Delivery (20)
Drug Development (57334)
Employer Resources (25)
FDA (13225)
Job Trends (10424)
News (271430)
Policy (22772)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1193)
Academic (1)
Accelerated approval (27)
ADA (22)
Adcomms (2)
Allergies (123)
Alliances (39406)
ALS (118)
Alzheimer's disease (1161)
Antibody-drug conjugate (ADC) (300)
Approvals (13854)
Artificial intelligence (499)
ASCO (200)
Autoimmune disease (224)
Automation (42)
Bankruptcy (278)
Best Places to Work (8121)
BIO (39)
BIOSECURE Act (1)
Biosimilars (119)
Biotechnology (98)
Bladder cancer (144)
Brain cancer (48)
Breast cancer (572)
Cancer (4311)
Cardiovascular disease (274)
Career advice (469)
Career pathing (7)
CAR-T (184)
CDC (2)
Celiac Disease (1)
Cell therapy (518)
Cervical cancer (43)
Clinical research (51236)
Collaboration (1504)
Company closure (1)
Compensation (1397)
Complete response letters (41)
COVID-19 (1130)
CRISPR (76)
C-suite (851)
Cystic fibrosis (97)
Data (6370)
Decentralized trials (1)
Denatured (6)
Depression (118)
Dermatology (69)
Diabetes (429)
Diagnostics (5862)
Digital health (52)
Diversity (4)
Diversity, equity & inclusion (8)
Drug discovery (207)
Drug pricing (13)
Drug shortages (5)
Duchenne muscular dystrophy (169)
Earnings (78679)
Editorial (5)
Employer branding (5)
Employer resources (26)
Events (97726)
Executive appointments (810)
FDA (16358)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (25)
Funding (1146)
Gene editing (146)
Generative AI (26)
Gene therapy (366)
GLP-1 (385)
Government (1934)
Grass and pollen (3)
Guidances (328)
Healthcare (11769)
Hematology (118)
HIV (56)
Huntington's disease (25)
IgA nephropathy (61)
Immunology and inflammation (121)
Immuno-oncology (60)
Indications (168)
Infectious disease (1346)
Inflammatory bowel disease (149)
Inflation Reduction Act (4)
Influenza (98)
Intellectual property (263)
Interviews (66)
IPO (13432)
IRA (7)
Job creations (2650)
Job search strategy (435)
JPM (7)
Kidney cancer (18)
Labor market (43)
Layoffs (131)
Leadership (3)
Legal (5960)
Liver cancer (54)
Longevity (19)
Lung cancer (587)
Lymphoma (284)
Machine learning (43)
Management (5)
Manufacturing (633)
Marketing (6)
MASH (130)
Medical device (13796)
Medtech (13968)
Mergers & acquisitions (16442)
Metabolic disorders (846)
mRNA (68)
Multiple sclerosis (126)
NASH (6)
Neurodegenerative disease (250)
Neuropsychiatric disorders (43)
Neuroscience (2148)
Neurotech (1)
NextGen: Class of 2026 (4038)
Non-profit (1486)
Now hiring (24)
Obesity (273)
Opinion (56)
Ovarian cancer (163)
Pain (203)
Pancreatic cancer (253)
Parkinson's disease (244)
Partnered (19)
Patents (496)
Patient recruitment (557)
Peanut (36)
People (47558)
Pharmaceutical (31)
Pharmacy benefit managers (10)
Phase 1 (16616)
Phase 2 (22809)
Phase 3 (15609)
Pipeline (7668)
Policy (43)
Postmarket research (1731)
Preclinical (7324)
Press Release (45)
Prostate cancer (236)
Psychedelics (11)
Radiopharmaceuticals (243)
Rare diseases (621)
Real estate (3871)
Recruiting (10)
Regulatory (18650)
Reports (23)
Research institute (1259)
Resumes & cover letters (74)
Rett syndrome (41)
RNA editing (10)
RSV (53)
Schizophrenia (103)
Series A (185)
Series B (147)
Service/supplier (5)
Sickle cell disease (63)
Special edition (5)
Spinal muscular atrophy (98)
Sponsored (16)
Startups (2704)
Stomach cancer (3)
Supply chain (59)
Tariffs (6)
The Weekly (5)
Vaccines (374)
Venture capital (35)
Weight loss (102)
Women's health (95)
Worklife (1)
Date
Today (40)
Last 7 days (331)
Last 30 days (1351)
Last 365 days (22190)
2026 (12342)
2025 (22294)
2024 (26511)
2023 (30712)
2022 (40189)
2021 (43048)
2020 (39889)
2019 (29802)
2018 (22439)
2017 (23952)
2016 (23395)
2015 (29695)
2014 (25645)
2013 (22111)
2012 (24411)
2011 (24636)
2010 (23591)
Location
Africa (383)
Alabama (73)
Alaska (4)
Arizona (319)
Arkansas (11)
Asia (25509)
Australia (3436)
California (12411)
Canada (3324)
China (740)
Colorado (542)
Connecticut (478)
Delaware (247)
Europe (43904)
Florida (1880)
Georgia (392)
Hawaii (2)
Idaho (49)
Illinois (823)
India (52)
Indiana (430)
Iowa (19)
Japan (428)
Kansas (111)
Kentucky (35)
Louisiana (38)
Maine (31)
Maryland (1419)
Massachusetts (8318)
Michigan (327)
Minnesota (670)
Mississippi (7)
Missouri (101)
Montana (22)
Nebraska (19)
Nevada (124)
New Hampshire (77)
New Jersey (2737)
New Mexico (19)
New York (3013)
North Carolina (1428)
North Dakota (6)
Northern California (6067)
Ohio (307)
Oklahoma (22)
Oregon (21)
Pennsylvania (2358)
Puerto Rico (24)
Rhode Island (41)
South America (572)
South Carolina (79)
South Dakota (1)
Southern California (5183)
Tennessee (145)
Texas (2036)
United States (41378)
Utah (388)
Vermont (2)
Virginia (175)
Washington D.C. (51)
Washington State (973)
West Virginia (2)
Wisconsin (111)
571,880 Results for "molecular devices inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
5 molecular glues that could stick—and the companies stuck in
Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
July 6, 2026
·
6 min read
·
Michael Gibney
Deals
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement will see Novartis pay $40 million upfront.
June 11, 2026
·
2 min read
·
Tristan Manalac
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.
May 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Sapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat Detection
July 14, 2026
·
2 min read
Press Releases
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
July 16, 2026
·
3 min read
Press Releases
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
January 5, 2026
·
4 min read
Press Releases
Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument
June 25, 2026
·
3 min read
Press Releases
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
July 16, 2026
·
6 min read
Press Releases
Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design
July 14, 2026
·
4 min read
Press Releases
United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
June 1, 2026
·
3 min read
1 of 57,188
Next
